Ad
related to: substitute for oxybutynin 10 mg imagegoodrx.com has been visited by 100K+ users in the past month
"Your pet's prescription needs met at a price you can afford." - Patch
- GoodRx®: Women’s Health
Save on Common Women’s Health Meds.
Find Resources You Can Count On.
- Healthcare Professionals
GoodRx® Can Help You Get Major
Savings For Your Patients
- Research You Can Rely On
Our team works hard to provide you
with the latest healthcare info.
- GoodRx® Blog
Get the Latest Healthcare News
Find What Matters Most to You
- GoodRx®: Women’s Health
Search results
Results from the WOW.Com Content Network
Oxybutynin, sold under the brand name Ditropan among others, is an anticholinergic medication primarily used to treat overactive bladder. It is widely considered a first-line therapy for overactive bladder due to its well-studied side effect profile, broad applicability, and continued efficacy over long periods of time.
Sleepiness is uncommon. [10] It is unclear if it is safe in pregnancy. [5] It appears safe in breastfeeding. [11] Greater care is recommended in those with heart problems. [12] It is an anticholinergic agent, [5] which does not have much effect on the brain. [13] Hyoscine butylbromide was patented in 1950, and approved for medical use in 1951. [14]
Mirabegron, sold under the brand name Myrbetriq among others, is a medication used to treat overactive bladder. [5] Its benefits are similar to antimuscarinic medication such as solifenacin or tolterodine. [6]
Solifenacin, sold as the brand name Vesicare [a] among others, is a medicine used to treat overactive bladder and neurogenic detrusor overactivity (NDO). [1] [2] It may help with incontinence, urinary frequency, and urinary urgency.
Propantheline bromide is an antimuscarinic medication used for the treatment of excessive sweating (hyperhidrosis), cramps or spasms of the stomach, intestines (gut), or bladder, and involuntary urination ().
A new opioid-free pain medication was approved by the U.S. Food and Drug Administration (FDA) on Thursday, marking a non-addictive alternative for patients. Journavx (suzetrigine), made by Vertex ...
Tolterodine, although it acts on all types of receptors, has fewer side effects than oxybutynin (M 3 and M 1 selective, but more so in the parotid than in the bladder) as tolterodine targets the bladder more than other areas of the body. [medical citation needed]
For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...